解放军医学院学报
解放軍醫學院學報
해방군의학원학보
Academic Journal of Chinese Pla Medical School
2015年
8期
797-800
,共4页
王志红%周宏伟%刘默%曹志刚%周敏航%邢丽%冯少美%古永建%彭朝津%孙君重%杨清明
王誌紅%週宏偉%劉默%曹誌剛%週敏航%邢麗%馮少美%古永建%彭朝津%孫君重%楊清明
왕지홍%주굉위%류묵%조지강%주민항%형려%풍소미%고영건%팽조진%손군중%양청명
吉西他滨%奈达铂%复发难治%非霍奇金淋巴瘤
吉西他濱%奈達鉑%複髮難治%非霍奇金淋巴瘤
길서타빈%내체박%복발난치%비곽기금림파류
gemcitabine%nedaplatin%relapse and refracatory%non-hodgkin lymphoma
目的：观察GNP(吉西他滨、奈达铂联合甲泼尼松龙)联合化疗治疗难治复发非霍奇金淋巴瘤的疗效。方法对本科2009年1月-2013年7月自愿接受GNP化疗的30例难治复发非霍奇金淋巴瘤住院患者进行疗效及不良反应的回顾性分析。其中难治12例，复发13例，进展5例。类型包括B细胞淋巴瘤18例，T细胞或NK/T细胞淋巴瘤12例。接受治疗的中位周期数为2(2~7)个疗程。结果2个周期GNP治疗，显示完全缓解(complete remission，CR)3例，部分缓解(partial remission，PR)20例，稳定(stable disease，SD)7例。总反应率(over response rate，ORR)为76.7%，1年总生存率(over survival，OS)为86.7%，无进展生存(progression- free survival，PFS)占40%，中位PFS为10个月(95% CI：5.8~14.2个月)。不良反应轻，耐受性良好。结论 GNP联合化疗治疗难治复发非霍奇金淋巴瘤可以取得良好的疗效。
目的：觀察GNP(吉西他濱、奈達鉑聯閤甲潑尼鬆龍)聯閤化療治療難治複髮非霍奇金淋巴瘤的療效。方法對本科2009年1月-2013年7月自願接受GNP化療的30例難治複髮非霍奇金淋巴瘤住院患者進行療效及不良反應的迴顧性分析。其中難治12例，複髮13例，進展5例。類型包括B細胞淋巴瘤18例，T細胞或NK/T細胞淋巴瘤12例。接受治療的中位週期數為2(2~7)箇療程。結果2箇週期GNP治療，顯示完全緩解(complete remission，CR)3例，部分緩解(partial remission，PR)20例，穩定(stable disease，SD)7例。總反應率(over response rate，ORR)為76.7%，1年總生存率(over survival，OS)為86.7%，無進展生存(progression- free survival，PFS)佔40%，中位PFS為10箇月(95% CI：5.8~14.2箇月)。不良反應輕，耐受性良好。結論 GNP聯閤化療治療難治複髮非霍奇金淋巴瘤可以取得良好的療效。
목적：관찰GNP(길서타빈、내체박연합갑발니송룡)연합화료치료난치복발비곽기금림파류적료효。방법대본과2009년1월-2013년7월자원접수GNP화료적30례난치복발비곽기금림파류주원환자진행료효급불량반응적회고성분석。기중난치12례，복발13례，진전5례。류형포괄B세포림파류18례，T세포혹NK/T세포림파류12례。접수치료적중위주기수위2(2~7)개료정。결과2개주기GNP치료，현시완전완해(complete remission，CR)3례，부분완해(partial remission，PR)20례，은정(stable disease，SD)7례。총반응솔(over response rate，ORR)위76.7%，1년총생존솔(over survival，OS)위86.7%，무진전생존(progression- free survival，PFS)점40%，중위PFS위10개월(95% CI：5.8~14.2개월)。불량반응경，내수성량호。결론 GNP연합화료치료난치복발비곽기금림파류가이취득량호적료효。
Objective To observe the efficacy of GNP (gemcitabine, nedaplatin, methyl prednisolone) combined chemotherapy in treatment for refractory and relapse non-hodgkin lymphoma (NHL).MethodsThe efficacy and adverse responses of 30 patients with refractory and relapse NHL who had voluntarily received GNP chemotherapy in our hospital from January 2009 to July 2013 were retrospectively analyzed. Of the 30 cases, 12 cases were refractory, 13 cases were relapse and 5 cases were progression. 18 cases were B cell lymphoma and 12 cases were T or NK/T cell lymphoma. The median circles of therapy-receiving were 2 circles (2-7 circles). ResultsThe efficacy of GNP combined chemotherapy in treatment for refractory and relapse NHL showed complete remission (CR) in 3 cases, partial remission (PR) in 20 cases, stable disease (SD) in 7 cases. The over response rate (ORR) was 76.7%, and the over survival rate for 1 year reached 86.7%. The progression free survival (PFS) reached 40% with the median PFS of 10 months (95%CI for 5.8- 14.2 months). The adverse responses were slight and the endurement wasfine.ConclusionThere is favorable efficacy for GNP combined chemotherapy in treatment for refractory and relapse non-hodgkin lymphoma.
